XtalPi
晶泰科技
Shenzhen-founded, HK-listed quantum-physics-plus-AI drug discovery platform serving most of global big pharma — the Shenzhen counterpart to Insilico for AI-native discovery, and a strong platform-benchmarking peer.
- Location
- International Biomedical Industrial Park, Futian District · Shenzhen
- Visit window
- From the Nanshan base · Jul 13–31
- Source status
- high confidenceprofiled
Next action
Prepare the private outreach route and meeting ask; keep contact details out of the app.
Why now: Visit window · From the Nanshan base · Jul 13–31
What they do
Provides AI- and quantum-physics-driven drug and materials R&D: uses quantum algorithms to compute molecular structures, feeds the data into its own AI models, and screens/generates candidate molecules — combining computation with automated ('dry + wet') robotic lab technology. Runs collaboration-based early discovery for pharma and materials clients, and now sells automated labs as installations abroad.
HKEX-listed since June 2024.
Why it matters
Maps onto Pure Advance's AI-discovery + biomanufacturing-automation thesis on two pillars: an AI-plus-quantum-physics discovery engine to benchmark, and automated 'scientist-robot' wet-labs relevant to pilot-scale/process interests. It already sells automated-lab + natural-bioactives-database infrastructure into the Gulf (a UAE royal-office deal) and runs a microbial organic-fertilizer collaboration for arid/desert regions across China and the Middle East — a rare operational GCC + microbial-manufacturing overlap.
Realistic entry is platform-access / a Saudi counterpart relationship, not peer co-development.
Visit objective & route
Substantive platform-access + GCC conversation: benchmark the quantum-physics-plus-AI and automated-lab platform, explore a Saudi/GCC localization relationship mirroring their UAE automated-lab model, and the microbial-biomanufacturing science overlap; secondary — a materials/formulation adjacency for topical care.
Approach route
Direct via the official contact channel to the overseas / Middle-East business line; frame as a platform-access + GCC conversation; visit the Futian HQ during the Shenzhen leg (note it is a cross-city ride from Nanshan).
Talking points
- Do you engage non-pharma / consumer or materials partners relevant to topical-care formulation, or only big-pharma discovery?
- Could your materials-science capability support formulation / delivery work for a topical product?
- Is a platform-learning / GCC-relationship meeting (not a transaction) appropriate, and is Futian the right visitor location?
- Reference the UAE automated-lab and natural-ingredient/halal angle to show fit for a Saudi counterpart relationship.
- Bring: Pure Advance one-pager (AI-accelerated microbial biocontrols) and an NDA template.
Open questions
- The right contact route for inbound foreign-founder / GCC enquiries (overseas-ME leads inferred from a single ceremony).
- Whether any KSA-specific activity exists — only UAE Gulf activity found so far.
- Whether they would engage a company at Pure Advance's scale for platform access vs. only large/sovereign clients.
- Confirm Futian is the right visitor site vs. another Shenzhen facility, and cross-city travel time from Nanshan.
- Exact magnitude/terms of the headline discovery deals against primary sources.
Risks & unknowns
- Large public company doing multi-billion-dollar / sovereign deals — realistic entry is platform-access or relationship, not a near-term transaction.
- Scale asymmetry: unclear they would engage a partner at Pure Advance's scale.
- Only UAE Gulf activity confirmed; no KSA-specific track record found yet.
- Named Middle-East contacts are inferred from one ceremony — routing is uncertain.
Private-pack boundary